A recent report in SCIENCE
is another example of ‘Big Pharma’ failing to address important public health
issues. The problem of resistance to
conventional antibiotics is reaching crisis proportions, accelerated by the
widespread use of antibiotics in mass agriculture. The technology to develop
powerful new drugs is there, but the profit motivation is not. In many respects this situation is similar to
the problem of developing medications for diseases such as malaria that
primarily affect poorer countries and thus provide little opportunity for large
profits. It is encouraging to learn that some governments are seeking ways to
break the roadblock on antibiotic development. However, is this enough? One might argue that this key area of drug
research be pursued through innovative public funding rather than be left to
the dictates of Wall Street.
http://www.sciencemag.org/content/348/6237/850.full
No comments:
Post a Comment